Due-Process-First KYC Compliance Platform for Fintechs
C5/10June 12, 2026
WhatA compliance-as-a-service platform for banks and fintechs that implements tiered KYC — minimal verification for low-risk activity, escalating only when legally required — reducing false positives and account freezes.
SignalCommenters are furious that KYC/AML gives private companies unchecked power to freeze accounts and deny service with no recourse, while sophisticated criminals like HSBC easily circumvent the rules — the system punishes ordinary people while failing at its stated goal.
Why NowRegulators in the EU and US are beginning to acknowledge proportionality principles in AML reform, and the crypto industry's battles over KYC have built political momentum for risk-based alternatives.
MarketFintechs and neobanks paying $50K-500K/year for compliance tooling; $15B+ regtech market. Incumbents like Chainalysis and Jumio are built around maximum-KYC, leaving a gap for proportional approaches.
MoatRegulatory approval and audit trail data create massive switching costs once a financial institution builds its compliance program around the platform.
CRISPR Delivery Platform for Solid Tumor TherapeuticsP7/10A biotech company focused specifically on solving the delivery problem for CRISPR-based cancer therapies, developing novel lipid nanoparticle or viral vector systems that can efficiently transport CRISPR payloads to solid tumors in vivo.
CRISPR Cancer Diagnostics for Undruggable MutationsP6/10A diagnostic platform that profiles patients' tumors for the specific genomic amplifications and mutations that CRISPR-shredding approaches can target, enabling oncologists to match patients to emerging CRISPR therapies.
Biotech Translation Tracker for Informed InvestorsC5/10A platform that tracks the real progress of preclinical and clinical-stage biotech breakthroughs — from lab results through delivery challenges, trial phases, and regulatory milestones — giving investors and patients an honest, hype-free assessment of how close therapies actually are to market.
Viral Vector Therapy Development Platform as ServiceC6/10A contract development platform that helps biotech startups and academic labs design, optimize, and manufacture viral vector (AAV/lentivirus) delivery systems for gene therapies, positioning as the picks-and-shovels play in gene therapy.
Automated Cost Guardrails for AI Agent OperationsP7/10A middleware layer that sits between AI agents and cloud/API services, enforcing hard spending limits, rate controls, and anomaly detection before any resource is consumed.
Prepaid Spending Caps for Cloud and API ServicesC6/10A financial wrapper service that lets developers provision hard-capped, prepaid budgets for cloud and API usage — once the balance hits zero, all calls stop instantly.